


## Supplementary Data



**SUPPLEMENTARY FIG. S1.** Percentage of origin of (A) MSC and (B) HPC for cell and engineered tissue therapies in Europe for the combined years of 2016 and 2017. BM, bone marrow; CB, chord blood; Fat, adipose tissue; HPC, hematopoietic progenitor cells; MSC, mesenchymal stromal/stem cells; PB, peripheral blood; Plac, placenta.